Core Viewpoint - Opus Genetics, a clinical-stage biopharmaceutical company, has announced a private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock at a price of $3.39 per share, aiming to raise approximately $25 million to fund its gene therapy programs and general corporate purposes [1][2]. Group 1: Private Placement Details - The private placement involves the issuance of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock, which will convert into common stock upon stockholder approval [1]. - The gross proceeds from the private placement are expected to be $25 million before deducting offering expenses [1]. - The financing is led by Adage Capital Management, with participation from Trails Edge Capital Partners and Marshall Wace [1]. Group 2: Use of Proceeds - The net proceeds from the private placement will be utilized to advance gene therapy clinical programs, as well as for working capital and general corporate purposes [2]. - The company anticipates that its pro forma cash balance of $70 million at year-end 2025 will fund operations into the first half of 2028, excluding potential proceeds from callable warrants or future milestone payments [2]. Group 3: Closing and Legal Aspects - The offering is expected to close on February 18, 2026, subject to customary closing conditions [3]. - Sidley Austin LLP is serving as counsel to Opus Genetics for this transaction, and the company did not use a placement agent [3]. - The shares issued in the private placement have not been registered under the Securities Act and may not be offered or sold in the U.S. without proper registration or exemption [4]. Group 4: Company Overview - Opus Genetics is focused on developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) [6]. - The company is working on seven AAV-based programs targeting various genetic causes of severe retinal disorders, including OPGx-LCA5 and OPGx-BEST1 [6]. - Additionally, Opus Genetics is advancing Phentolamine Ophthalmic Solution 0.75% for pharmacologically induced mydriasis, with potential applications in presbyopia and low-light visual disturbances [6].

Core Insights - Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases (IRDs) [4] Company Overview - The company is developing durable, one-time treatments that target the underlying genetic causes of severe retinal disorders [4] - Opus Genetics has a pipeline that includes seven AAV-based programs, with key candidates such as OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration [4] - The company is also advancing Phentolamine Ophthalmic Solution 0.75%, which is an approved therapy for pharmacologically induced mydriasis, with potential additional indications in presbyopia and low-light visual disturbances following keratorefractive surgery [4] Upcoming Conferences - Leadership team members will participate in several conferences, including the Collaborative Community on Ophthalmic Innovation (CCOI) and the Asia-Pacific Academy of Ophthalmology Congress (APAO) from February 3-8, 2026, in Hong Kong [2][5] - The company will engage with the global ophthalmology community to discuss advances in gene therapy and evolving strategies for treating inherited retinal disorders [5] - Chris Ernst, Chief Technology Officer, will present on building scalable viral vector manufacturing models on February 11, 2026, in San Diego, CA [5] - Mark Pennesi, M.D., Ph.D., will present preliminary results from a Phase 1b/2a clinical study of OPGx-BEST1 gene therapy on February 27, 2026, in San Diego, CA [5]

Core Insights - Opus Genetics, Inc. has launched a clinical trial for a gene therapy targeting MERTK-related retinitis pigmentosa, a rare inherited eye disease that leads to progressive vision loss and blindness [1][3][4] Company Overview - Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases (IRDs) [6][8] - The company is working on a pipeline that includes seven AAV-based programs, with OPGx-MERTK being a key candidate for MERTK-related retinitis pigmentosa [6][8] Clinical Trial Details - The clinical trial will assess the safety and efficacy of OPGx-MERTK, which uses an adeno-associated virus (AAV) to deliver a functional copy of the MERTK gene to retinal cells [3][4] - The trial is set to begin in 2026 at Cleveland Clinic Abu Dhabi, which will serve as the clinical site [2][7] Collaboration and Impact - The trial is being conducted in collaboration with the Department of Health – Abu Dhabi, Cleveland Clinic Abu Dhabi, and other local partners, highlighting Abu Dhabi's commitment to precision medicine and rare disease innovation [2][5] - MERTK-related retinitis pigmentosa affects approximately 60,000 patients globally, and this trial represents a significant opportunity to address an unmet medical need [4][7]

Core Insights - Opus Genetics is advancing its gene therapy pipeline aimed at treating inherited retinal diseases (IRDs) with significant milestones achieved in 2025 and upcoming catalysts in 2026 [1][3] Pipeline Progress - In 2026, Opus is set to announce clinical data from its BEST1 program and move its LCA5 program into pivotal testing, targeting FDA approval [2] - The company has multiple programs that may qualify for Rare Pediatric Disease designation, potentially leading to Priority Review Vouchers (PRV) for non-dilutive capital [2] Corporate Achievements - 2025 was marked by strong execution, with two gene therapies advancing in clinical trials and an FDA application submitted for a partnered commercial product, indicating a large market opportunity [3] - The company secured approximately $23 million in gross proceeds through a registered direct offering, raising its total cash position to over $50 million, which is expected to fund operations into the second half of 2027 [10] Clinical Trials and Data - The OPGx-BEST1 program is currently in a Phase 1/2 trial (BIRD-1) with initial data expected in mid-2026, and it is potentially eligible for multiple regulatory designations [8][11] - OPGx-LCA5 is advancing into a pivotal Phase 3 trial, with positive data reported in pediatric participants and durable improvements in adult cohorts [12] Financial Outlook - As of September 30, 2025, Opus Genetics had cash and cash equivalents of $30.8 million, with a total cash position exceeding $50 million after recent fundraising [10]

Core Insights - Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases [3] Company Overview - The company is developing durable, one-time treatments that target the underlying genetic causes of severe retinal disorders [3] - Opus Genetics has a pipeline that includes seven AAV-based programs, with key candidates such as OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration [3] - Additional candidates in development target RHO, RDH12, and MERTK mutations [3] - The company is also advancing Phentolamine Ophthalmic Solution 0.75%, which is an approved therapy for pharmacologically induced mydriasis, with further indications in late-stage development for presbyopia and low-light visual disturbances following keratorefractive surgery [3] - Opus Genetics is headquartered in Research Triangle Park, NC [3] Upcoming Events - George Magrath, M.D., the CEO of Opus Genetics, will present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, at 8:15 a.m. PT [1]

Core Insights - Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases [3] Company Overview - The company is developing durable, one-time treatments that target the underlying genetic causes of severe retinal disorders [3] - Opus Genetics has a pipeline that includes seven AAV-based programs, with key candidates such as OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration [3] - Additional candidates in development target RHO, RDH12, and MERTK mutations [3] - The company is also advancing Phentolamine Ophthalmic Solution 0.75%, which is an approved therapy for pharmacologically induced mydriasis, with further indications in late-stage development for presbyopia and low-light visual disturbances following keratorefractive surgery [3] - Opus Genetics is headquartered in Research Triangle Park, NC [3] Upcoming Events - George Magrath, M.D., the CEO of Opus Genetics, will present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, at 8:15 a.m. PT [1]

Core Insights - Opus Genetics has received a positive recommendation from the Independent Data Monitoring Committee (IDMC) to continue its Phase 1/2 BEST1 clinical trial (BIRD-1) for the gene therapy OPGx-BEST1 aimed at treating Best disease [1][2][3] Company Overview - Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) [7] - The company is advancing a pipeline that includes seven AAV-based programs, with OPGx-BEST1 targeting BEST1-related retinal degeneration [7] Clinical Trial Details - The BIRD-1 trial is a multi-center, adaptive, open-label, dose-exploring study evaluating the safety, tolerability, and preliminary efficacy of OPGx-BEST1 in participants with Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) [5] - Treatment involves a single subretinal injection in one eye of each participant, with two dosing cohorts being explored [5] Disease Background - Best disease, or vitelliform macular dystrophy, is a rare inherited retinal condition caused by mutations in the BEST1 gene, leading to progressive vision loss and potential blindness [6] - Approximately 9,000 patients in the United States are affected by BEST1-related inherited retinal diseases [6]

Core Insights - Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases (IRDs) [4] Company Overview - The company is developing durable, one-time treatments that target the underlying genetic causes of severe retinal disorders [4] - Opus Genetics has a pipeline that includes seven AAV-based programs, with key candidates being OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration [4] - Additional candidates in development target RHO, RDH12, and MERTK [4] - The company is also advancing Phentolamine Ophthalmic Solution 0.75%, which is approved for pharmacologically induced mydriasis, with further indications in late-stage development for presbyopia and low-light visual disturbances following keratorefractive surgery [4] - Opus Genetics is headquartered in Research Triangle Park, NC [4] Upcoming Events - Management will participate in the BTIG 5th Annual Ophthalmology Day on December 1, 2025, with Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, in a fireside chat at 1:00 p.m. ET [2] - George Magrath, M.D., Chief Executive Officer, will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:00 a.m. ET in New York, NY [2] - A link to the live and archived webcast for the Piper Sandler conference will be available on the company's website under the Investors section [3]

Core Insights - Opus Genetics has reported positive clinical data from its OPGx-LCA5 Phase 1/2 trial, indicating potential for restoring cone-mediated vision in patients with inherited retinal diseases [1][6] - The company successfully completed a Type B Regenerative Medicine Advanced Therapy (RMAT) meeting with the FDA, which may facilitate an accelerated regulatory pathway for OPGx-LCA5 [1][6] Pipeline Updates - The OPGx-LCA5 program is focused on gene therapy for Leber Congenital Amaurosis (LCA) and has shown significant improvements in visual function in both pediatric and adult participants [3][6] - Recruitment is ongoing for the OPGx-BEST1 gene therapy program, targeting BEST1-related inherited retinal diseases [4][5] - The company plans to submit a Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for presbyopia treatment by the end of 2025 [5][8] Financial Results - As of September 30, 2025, Opus Genetics reported cash and cash equivalents of $30.8 million, with an additional $23.0 million raised through a direct equity offering [10] - License and collaborations revenue for Q3 2025 was $3.1 million, a decrease from $3.9 million in Q3 2024, primarily due to lower research and development service reimbursements [11] - General and Administrative expenses increased to $5.0 million in Q3 2025 from $2.9 million in Q3 2024, attributed to higher legal, payroll, and professional service costs [12] - Research and Development expenses decreased to $6.4 million in Q3 2025 from $9.0 million in Q3 2024, reflecting lower costs in clinical research and manufacturing [13] Net Loss - The net loss for Q3 2025 was $17.5 million, or $(0.25) per share, compared to a net loss of $7.5 million, or $(0.29) per share, in Q3 2024 [15][20]

Core Insights - Opus Genetics has successfully completed a Type B Regenerative Medicine Advanced Therapy (RMAT) meeting with the FDA regarding its gene therapy candidate OPGx-LCA5 for Leber congenital amaurosis (LCA) caused by mutations in the LCA5 gene [1][2][8] - The FDA provided constructive feedback on Opus's registration strategy, including Chemistry, Manufacturing and Controls (CMC), and pivotal trial design, acknowledging the significant unmet medical need for individuals with LCA5-related blindness [2][3] - The company plans to advance its ongoing trial using an adaptive design that includes a Phase 3 portion, which will avoid the need for a separate registrational trial [3][4] Clinical Development - Six late-stage participants have been treated in the Phase 1/2 trial of OPGx-LCA5, with all experiencing clinically meaningful improvements in vision [3][9] - The Phase 3 trial will include a run-in period to evaluate the natural history of each participant, serving as their own control [5][4] - Efficacy and safety will be assessed using various measures, including visual acuity and microperimetry, with dosing anticipated in the second half of 2026 [5][8] Financial Position - Opus Genetics has secured recent financing of $23 million, which will support the advancement of its LCA5 program and fund current operating plans into the second half of 2027 [6][8] Regulatory Environment - The FDA's introduction of the Rare Disease Evidence Principles (RDEP) review process aims to facilitate the approval of drugs for rare diseases, and Opus believes its LCA5 program meets the eligibility criteria for this process [7][8] - OPGx-LCA5 has the potential to be the first gene therapy and one-time treatment for LCA type 5, addressing a significant unmet medical need [8][11] Company Overview - Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases and small-molecule therapies for other ophthalmic disorders [12] - The company's pipeline includes AAV-based gene therapies targeting conditions such as LCA and bestrophinopathy, with OPGx-LCA5 currently in a Phase 1/2 clinical trial [12][9]